ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma

Tanaka, Miwa; Chuaychob, Surachada; Homme, Mizuki; Yamazaki, Yukari; Lyu, Ruyin; Yamashita, Kyoko; Ae, Keisuke; Matsumoto, Seiichi; Kumegawa, Kohei; Maruyama, Reo; Qu, Wei; Miyagi, Yohei; Yokokawa, Ryuji; Nakamura, Takuro

doi:10.1038/s41467-023-37049-z

Download PDF

Article
Open Access
Published: 07 April 2023

ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma

Nature Communications volume 14, Article number: 1957 (2023) Cite this article

1164 Accesses
49 Altmetric
Metrics details

Subjects

Abstract

Alveolar soft part sarcoma (ASPS) is a soft part malignancy affecting adolescents and young adults. ASPS is characterized by a highly integrated vascular network, and its high metastatic potential indicates the importance of ASPS’s prominent angiogenic activity. Here, we find that the expression of ASPSCR1::TFE3, the fusion transcription factor causatively associated with ASPS, is dispensable for in vitro tumor maintenance; however, it is required for in vivo tumor development via angiogenesis. ASPSCR1::TFE3 is frequently associated with super-enhancers (SEs) upon its DNA binding, and the loss of its expression induces SE-distribution dynamic modification related to genes belonging to the angiogenesis pathway. Using epigenomic CRISPR/dCas9 screening, we identify Pdgfb, Rab27a, Sytl2, and Vwf as critical targets associated with reduced enhancer activities due to the ASPSCR1::TFE3 loss. Upregulation of Rab27a and Sytl2 promotes angiogenic factor-trafficking to facilitate ASPS vascular network construction. ASPSCR1::TFE3 thus orchestrates higher ordered angiogenesis via modulating the SE activity.

Introduction

Tumor angiogenesis is one of the most important processes in malignant progression and distant metastasis of cancer¹. Migration, extension, and sprouting of endothelial cells are key mechanisms that initiate angiogenesis to construct vascular tubes that are required for oxygen and nutrition transport to cancer cells as well as cancer-cell intravasation². However, this cancer-induced neovascularization frequently induces the construction of fragile blood vessels that exhibit abnormal distributions and reduced pericyte numbers, resulting in frequent vessel destruction and obstruction and insufficient blood supply in common cancers^3,4. In contrast, there is a group of cancers that induce abundant and highly integrated blood vessels with abundant pericyte wrapping, and the presence of the pericytes and their derivatives affects the malignant potential of cancer. The group includes cancers originating from blood vessel-rich organs, such as the kidney, liver, and endocrine organs^5,6,7. These cancers further demonstrate distinct metastatic phenotypes, maintaining epithelioid structures unrelated to epithelial mesenchymal transition^7,8. The pericyte that wraps around the vascular tube plays a key role in angiogenic initiation and vessel stability in both neoplastic and non-neoplastic conditions^4,9. Platelet-derived growth factor β (PDGFB), which is provided by both cancer cells and non-cancerous stromal cells, is important for pericyte recruitment, and the interaction between PDGFB and PDGF receptor β (PDGFRB) on pericytes is responsible for mature-blood-vessel stabilization^10,11.

Alveolar soft part sarcoma (ASPS) is a slow-growing malignant neoplasm affecting adolescents and young adults^12,13. Despite its less aggressive nature in the primary site, ASPS is a highly metastatic tumor, and patients exhibit poor outcomes due to the limitations of the current therapies^14,15,16. ASPS is characterized by a blood vessel-rich alveolar structure with a highly integrated vascular network, which is responsible for frequent metastasis^13,17. Blood-vessel abundance in ASPS suggests that the vascular network is an ideal target for effective therapies; however, vascular endothelial growth factor receptor (VEGFR)-inhibitor administration has not provided a cure for ASPS^14,16,18. These findings indicate that there is an unknown ASPS angiogenic mechanism that should be clarified to facilitate enhanced therapy.

We established a mouse model for human ASPS¹⁷ that effectively recapitulates ASPS phenotypes, such as alveolar structure with fine capillary network, frequent intra- and extravasation of tumor nests, and distant metastasis. Importantly, tumor-blood-vessel analysis in the mouse model and human ASPS clarified that these vessels are well encapsulated with PDGFRB- and smooth muscle actin-positive pericytes, and that tumor-cell enclosure by pericytes is observed in the blood stream during distant metastasis. The study revealed the unique angiogenic process in ASPS and underscored the importance of angiogenesis in ASPS development and progression.

ASPS is invariably associated with ASPSCR1 and TFE3 gene fusion due to t(X;17) chromosomal translocation¹⁹. ASPSCR1::TFE3 encodes an oncogenic transcription factor using TFE3’s basic helix-loop-helix (bHLH) domain as a DNA-binding domain^20,21. Like other sarcoma-associated fusion genes, ASPSCR1::TFE3 is essential for transforming target cells to induce ASPS in vivo^17,22. As an aberrant MiT/TFE3 family transcription factor, ASPSCR1::TFE3 regulates genes involved in lysosomes, autophagy, and angiogenesis^17,21,23,24. ASPSCR1::TFE3 also upregulates genes important for angiogenesis and tumor metastasis, such as PDGFB, ANGPTL2, and GPNMB^17,24,25, suggesting that ASPSCR1::TFE3 plays a central role in the angiogenesis characteristic of ASPS. In addition, its function in rather restricted cells-of-origin, such as embryonic mesenchymal cells, suggests that a proper epigenetic environment is important for the oncogenic and angiogenic function of ASPSCR1::TFE3.

Despite the strong circumstantial evidence for the association between ASPSCR1::TFE3 and angiogenesis, the mechanism by which ASPSCR1::TFE3 orchestrates angiogenesis in association with the proper epigenetic conditions remains unclear. Previous studies on oncogenic fusion transcription factors, such as EWSR1::FLI1 in Ewing sarcoma, have indicated that the functions of these transcription factors frequently interact with pre-existing and/or novel super-enhancers (SEs)²⁶.

In this study, we investigate the epigenetic landscape of mouse and human ASPS as well as genome wide DNA binding of ASPSCR1::TFE3. Interestingly, the expression of ASPSCR::TFE3 is dispensable for tumor-cell maintenance in vitro; however, its expression is required for in vivo tumorigenesis and angiogenesis, and ASPSCR1::TFE3-expression loss induces drastic modifications in SE distribution. Therefore, to understand how ASPSCR1::TFE3 induces angiogenesis, we investigate the target SEs and downstream genes involved in angiogenesis using our ASPS model and an innovative organ-on-a-chip system.

Results

ASPSCR1::TFE3 is dispensable for cell growth and survival of ASPS cells in vitro but required for in vivo tumorigenesis

In our previous study, ASPSCR1::TFE3 expression in murine embryonic mesenchymal cells could effectively induce highly metastatic tumors with human ASPS phenotypes when they were transplanted into nude and Balb/c mice¹⁷. These sarcoma cells proliferate well in vitro and are serially transplantable. However, we observed frequent ASPSCR1::TFE3-expression loss or decrease in 21 of 32 cell lines during in vitro passage (Fig. 1, a–c). There were no significant differences in cell proliferation or morphology (Fig. 1d, Supplementary Fig. 1a, c). When ASPSCR1::TFE3 was knocked down in the human ASPS-KY or ASPS1 cell lines, the in vitro growth potential was not significantly affected (Fig. 1d, Supplementary Fig. 1c). Moreover, acute loss of ASPSCR1::TFE3 expression by siRNA-mediated knockdown in murine ASPS17 and ASPS25 cells did not affect cellular growth significantly (Supplementary Fig. 1d). Although the cause of the frequent ASPSCR1::TFE3-expression loss has not been fully clarified, we detected a loss of the 5’ long terminal repeat promoter/enhancer of the retroviral vector used for ASPSCR1::TFE3 transduction in at least one pair of murine ASPS cell lines, ASPS17 and ASPS17 null (null) (Supplementary Fig. 1b). These results indicate that ASPSCR1::TFE3 expression is dispensable for in vitro ASPS-cell growth once they are transformed. In contrast, no tumor growth was observed when ASPS null cells were transplanted into nude mice (Fig. 1e). Histological examination of early tumorigenic lesions 4 and 14 days after transplantation revealed that FLAG-positive ASPS-cell foci were accompanied by Cd31-positive endothelial cells and Pdgfrb-positive pericytes in the ASPS17 transplanted areas, whereas no FLAG-positive cells and very few Cd31-positive and Pdgfrb-positive blood vessel components were observed in the subcutaneous part of ASPS null transplanted recipients (Fig. 1f, Supplementary Fig. 1e). Gene expression profiling revealed significant upregulation and downregulation of genes according to the ASPSCR1::TFE3 status. We found 2,572 upregulated genes and 3,308 downregulated genes (1.5-fold threshold) in ASPS17 cells compared with those in ASPS null cells as well as 1583 downregulated and 2,102 upregulated genes (1.2-fold threshold) in ASPS-KY cells by knockdown of ASPSCR1::TFE3 (Supplementary Data 1–4). Gene set enrichment analysis (GSEA) revealed enrichment of angiogenesis-related pathways, such as the VEGF, PDGF, and intracellular vesicle/granule-related pathways (Fig. 1g, Supplementary Fig. 1f, g). Similar enrichment results were obtained in the ASPSCR1::TFE3 knockdown experiment using the human ASPS-KY and ASPS1 cell lines (Fig. 1h, Supplementary Fig. 1h, i). Downregulated expression of individual genes in these pathways such as Rab27a, Sytl2, Pdgfb, Vwf, and Gpnmb was confirmed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) (Fig. 1g, h, Supplementary Fig. 1f, g, h, i). Common genetic pathways were observed according to the ASPSCR1::TFE3 expression status among mouse and human ASPS cell lines (Supplementary Fig. 1j). Collectively, these results suggest that ASPSCR1::TFE3 regulates downstream target genes involved in angiogenesis to induce ASPS’s blood-vessel-rich alveolar structure and in vivo tumorigenesis.

**Fig. 1: *ASPSCR1::TFE3* expression is dispensable for cell maintenance in vitro but required for in vivo tumor development in ASPS.**

ASPSCR1::TFE3 affects chromatin remodeling and activates its downstream target genes

ASPSCR1::TFE3 binds DNA using TFE3-derived basic helix-loop-helix (bHLH) and leucin zipper domains and modulates downstream-target-gene expression²¹. Drastic modulation of gene expression profiles in the absence of ASPSCR1::TFE3 suggests that chromatin activity may be affected. ChIP-seq analysis demonstrated that ASPSCR1::TFE3 binding peaks were predominantly associated with distal regions (69–78%) and 16–22% of the peaks were located at gene promoters both in mouse ASPS17 and human ASPS-KY cells (Fig. 2a). The Genomic Regions Enrichment of Annotations Tool (GREAT) pathway analysis for these ASPSCR1::TFE3 binding peaks identified genes involved in lysosomes, cytoplasmic vesicles, or vacuolar membranes, whose expression was upregulated in ASPS (Supplementary Fig. 2a). The consensus binding motif for the MiT/TFE family transcription factors, CACGTGAC, was most highly enriched in mouse and human ASPS (Fig. 2b). Previous studies have suggested that target-gene upregulation by ASPSCR1::TFE3 plays an important role in the ASPS development^17,21,23. We subsequently examined the association between ASPSCR1::TFE3 and histone H3K27ac-binding signals in both mouse and human ASPS. A frequent association between ASPSCR1::TFE3 and H3K27ac binding was observed (75% and 85% of ASPSCR1::TFE3 binding in mice and humans, respectively) (Fig. 2c, d). H3K27ac-binding signals around the ASPSCR1::TFE3 binding regions were significantly reduced by loss of or diminished ASPSCR1::TFE3 expression (Fig. 2d, Supplementary Fig. 2b, c) while the total number of H3K27ac-binding peaks was not reduced (Supplementary Fig. 2b), suggesting that ASPSCR1::TFE3 potentially modulates global histone modifications and chromatin activation. Thereafter, we compared SE profiles between ASPS17 and ASPS null cells and found that 49% of SEs were lost by loss of ASPSCR1::TFE3-expression (Fig. 2e, f, Supplementary Data 5–7). Pathway analysis of 258 SEs that disappeared after ASPSCR1::TFE3 loss revealed blood vessel-related pathway enrichment (Fig. 2f, g, Supplementary Fig. 2d). Significant differences in SE distribution were also evident in human ASPS cells after TFE3 knockdown (Supplemental Fig. 2e). Pathway analysis of ASPSCR1::TFE3-positive SEs revealed overlapping blood vessel activity-associated pathway enrichment (Supplementary Fig. 2f, g). These results strongly suggest that ASPSCR1::TFE3 partially regulates angiogenesis-associated target genes by modulating SE.

**Fig. 2: The loss of *ASPSCR1::TFE3* expression modulates distribution of super-enhancers (SEs).**

The BET protein inhibitor JQ1 suppresses angiogenesis-associated SEs and inhibits ASPS in vivo growth

SEs are cis-regulatory elements targeted by the core regulatory circuitry and mediator complex²⁷. BET-domain proteins play an important role in the SE functions, and the inhibition of their activities renders them effective targets for the SE-associated malignant potential of cancer^27,28. In vivo treatment of murine and human ASPS cells transplanted into nude mice with JQ1, a BET-domain inhibitor, significant suppressed tumor growth (Fig. 3a, Supplementary Fig. 3a). This growth suppression was accompanied by remarkable angiogenic inhibition, exhibiting a reduction in CD31-positive endothelial cells and PDGFRB- or alpha-smooth muscle actin (aSMA)-positive pericytes (Fig. 3b, Supplementary Fig. 3b). Gene expression analysis of JQ1-treated ASPS cells in vitro using GSEA and Ingenuity Pathway Analysis (IPA) demonstrated PDGF-associated and angiogenesis-related pathway enrichment (Fig. 3c, d, Supplementary Fig. 3c). Brd4 is a major JQ1 target, and ChIP-seq analysis revealed a significant reduction in Brd4 binding around the ASPSCR1::TFE3 binding peaks in mouse and human ASPS (Fig. 3e, Supplementary Fig. 3d). A total of 23,924 out of 34,800 Brd4-binding peaks disappeared after JQ1 treatment, and the GREAT analysis of these peaks revealed angiogenesis-related pathway enrichment (Fig. 3f). Moreover, the involvement of JQ1 suppressed Brd4 binding, and the angiogenesis pathway was affected in an ASPSCR1::TFE3-dependent manner (Supplementary Fig. 3e). In addition, Brd4-binding signals within SEs were significantly decreased by JQ1 treatment (Supplementary Fig. 3f, g). ChIP-seq analysis also demonstrated that Brd4-binding signals were reduced in SEs and active enhancers associated with ASPSCR1::TFE3 target genes, namely, Rab27a, Sytl2, Pdgfb, and Vwf, whose expression was downregulated by ASPSCR1::TFE3 loss (Fig. 3g, h, Supplementary Fig. 3h, i). In contrast, there was also a subset of genes, including Myh9 and Neat1 whose enhancers were not affected by the JQ1 treatment. Although it is reported that JQ1 treatment suppresses tumor growth through downregulation of c-Myc expression²⁹, c-Myc expression remained unchanged in mouse and human ASPS cells (Supplementary Fig. S3j). The CDK7/8 inhibitor, THZ1, which also targets SEs in certain cancers³⁰, did not exhibit growth suppressive effects on ASPS or angiogenesis-related gene downregulation (Supplementary Fig. 3k, l), suggesting that chromatin modifications on angiogenesis-associated SEs by ASPSCR1::TFE3 may be effective in a Brd4-specific manner. Overall, JQ1 treatment targets SEs associated with ASPSCR1::TFE3-related angiogenic function, and the results underscore the usefulness of epigenetic ASPS therapies.

**Fig. 3: JQ1 suppresses angiogenesis-associated SEs and inhibits ASPS in vivo growth.**

Epigenomic CRISPR screening identifies ASPSCR1::TFE3 target genes involved in angiogenesis and in vivo tumor development

SE modification by ASPSCR1::TFE3 and JQ1 treatment strongly suggests that downstream target genes regulated by these SEs play a critical role in ASPS-related angiogenesis, and that the identification of these targets will inform future ASPS therapies. Therefore, epigenetic CRISPR screening with dCas9-KRAB was performed to identify ASPSCR1::TFE3 targets that are required for angiogenesis and in vivo tumor growth. A total of 494 SEs and active enhancers in which H3K27ac signals were reduced by >40% due to ASPSCR1::TFE3 loss were selected, and 7716 gRNAs (average 12.8 per enhancer) were designed to target these enhancers (Fig. 4a, Supplementary Data 8). To suppress target-enhancer activities, ASPS17 cells were introduced with lentiviral vectors bearing gRNAs and dCas9-KRAB, and pools of lentivirus-transduced cells were transplanted into nude mice (Supplementary Fig. 4a). Locus-specific repression effects were confirmed by introducing individual lentiviruses (Supplementary Fig. 4b). We applied Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) algorithm³¹ to identify 45 loci with significantly depleted gRNAs in tumors (Fig. 4b, c, Supplementary Fig. 4c, Supplementary Data 9 and 10). Topologically associated domains (TADs) were defined by Hi-C analysis (Fig. 4d), and 271 candidate target genes included in the same TAD as each SE were selected. Forty-four candidate genes were further selected by downregulated expression in ASPS null cells and 25 genes were found upregulated in human ASPS samples comparing with other types of sarcoma (Fig. 4e, Supplementary Fig. 4i, Supplementary Data 11). Six candidate genes, namely, Ccbe1, Pdgfb, Rab27a, Syngr1, Sytl2, and Vwf, were finally selected by functional annotations and subjected to an in vivo validation assay. After effective knockout of each gene was validated (Supplementary Fig. 4d, e), the tumor clones were transplanted into nude mice, and tumor growth was monitored daily. Despite comparable proliferation rates in vitro (Supplementary Fig. 4f), significant suppression of in vivo tumor development was observed by Pdgfb, Rab27a, Sytl2, and Vwf knockout (Fig. 4f). As shown by ASPSCR1::TFE3-expression loss and JQ1 treatment, tumor-growth suppression by each knockout cell was accompanied by significant angiogenic inhibition (Supplementary Fig. 4g). The vascular structure of ASPS is characterized by a highly integrated vessel system comprising pericytes and endothelial cells. The present epigenetic screening identified Sytl2 and Rab27a, both of which are involved in intracellular trafficking of cytoplasmic vesicles³², as well as angiogenic factors Pdgfb and Vwf, indicating that the ASPSCR1::TFE3-modulated chromatin activity orchestrates the core angiogenesis program of ASPS.

**Fig. 4: Identification of ASPSCR1::TFE3 targets by epigenomic CRISPR/dCas9 screening.**

To evaluate the expression status of ASPSCR1::TFE3 target genes identified in the present study, their expression was examined using clinical bone and soft part sarcoma samples and human sarcoma cell lines. Increased RAB27A, SYTL2, and VWF expression was observed in human ASPS among the six sarcoma types (Fig. 4g). PDGFB expression in ASPS was the second highest following dermatofibrosarcoma protuberance, in which PDGFB fuses with COL1A1 and is highly upregulated³³. Upregulated RAB27A, SYTL2, and VWF expression was confirmed in two human ASPS cell lines, ASPS-KY and ASPS1, in comparison with two Ewing sarcomas, two synovial sarcomas, and one osteosarcoma cell line (Supplementary Fig. 4h). No significant differences were observed in PDGFB expression among ASPS, Ewing, and synovial sarcoma cells. Upregulation of RAB27A, SYTL2, PDGFB, and VWF in human ASPS was observed when expression of these four genes was compared among five sarcoma types using microarray data deposited to Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) (Supplementary Fig. 4i). Immunohistological examination revealed diffuse cytoplasmic RAB27A and SYTL2 staining, in accordance with their upregulated expression (Fig. 4h). VWF was also positive with focally strong staining. The mechanism of uneven VWF accumulation remains unclear, and the clarification of its relationship with endothelial sprouting is rather intriguing.

Intracellular trafficking of angiogenic factors is promoted by the Rab27a/Sytl2 axis

As described previously, the small GTPase protein Rab27a binds to cytoplasmic vesicles and facilitates their trafficking to the plasma membrane in collaboration with Sytl/Slp family proteins³². To clarify the role of the Rab27a/Sytl2 axis in ASPS, Pdgfb and Gpnmb secretion was examined, since Gpnmb is important for extravasation of tumor cells¹⁷. Rab27a or Sytl2 knockouts significantly suppressed Pdgfb and Gpnmb secretion (Fig. 5a). A co-immunoprecipitation experiment showed interaction between Rab27a and Sytl2, and the Rab27a W73G mutant, in which the binding activity for Sytl2 was lost³⁴, failed to exhibit increased secretion activity (Fig. 5a, Supplementary Fig. 5a, b). Rab27a, Sytl2, or Pdgfb knockout and ASPSCR1::TFE3 loss resulted in decreased pericyte growth induction when these cells’ conditioned media were used (Fig. 5b), suggesting that the secretion of growth factors such as Pdgfb may be induced by ASPSCR1::TFE3 via upregulation of downstream target genes. Thereafter, Pdgfb and Gpnmb intracytoplasmic trafficking was examined in ASPS17, Rab27a knockout, Sytl2 knockout, and ASPS null cells. Fluorescence recovery after photobleaching (FRAP) significantly delayed Pdgfb, Gpnmb, Angptl2 in Rab27a knockout, Sytl2 knockout, and ASPS null cell membrane trafficking (Fig. 5c, d, Supplementary Fig. 5c). Rab27a re-expression rescued Pdgfb and Gpnmb trafficking, whereas the W73G mutant did not (Supplementary Fig. 5d). Likewise, von Willebrand factor (VWF) secretion was also significantly reduced by Rab27a and Sytl2 knockout and by ASPSCR1::TFE3-expression loss (Fig. 5e). Although its large molecular weight precluded the FRAP assay, the intra-cytoplasmic distribution of VWF indicated that VWF is predominantly localized in the perinuclear region in ASPSCR1::TFE3-, Rab27a-, or Sytl2-reduced conditions (Fig. 5f, Supplementary Fig. 5e). Nexinhib 20, a small-molecule inhibitor for the interaction between Rab27a and Sytl1 (Supplementary Fig. 5f), a close Sytl2 homolog³⁵, suppressed Pdgfb, Gpnmb, and VWF secretion and Pdgfb, Gpnmb, and Angptl2 in membrane trafficking in ASPS 17 cells (Fig. 5g, h, Supplementary Fig. 5g). Overall, these results indicate that intracytoplasmic trafficking of angiogenic factors, such as Pdgfb, Gpnmb, Angptl2, and Vwf, is promoted in ASPS cells and regulated by ASPSCR1::TFE3 via the Rab27a/Sytl2 axis.

Rab27a or Sytl2 loss affects vascular sprouting in the microfluidic device

To confirm the significant role of the Rab27a/Sytl2 axis in angiogenesis, three-dimensional (3D) tissue culture/microfluidic devices were used to mimic in vivo angiogenesis. The microfluidic device included a tumor spheroid comprising murine ASPS cells covered with pericytes to constitute “core shell” structures (Fig. 6a, b, c, Supplementary Fig. 6a). Spheroid growth varied, despite the equal growth property and ASPSCR1::TFE3 expression of each ASPS clone (Supplementary Fig. 6a, b). The tumor spheroids were subsequently co-cultured with human umbilical vein endothelial cells (HUVEC) to evaluate the on-chip vascular extension. During 5 days of co-culturing, significant HUVEC sprouting toward the tumor spheroids of ASPS cells occurred; however, the sprouting effect was significantly suppressed by Rab27a or Sytl2 knockout and ASPSCR1::TFE3-expression loss (Fig. 6d, e, Supplementary Fig. 6c). Decreases in vascular components of Rab27a or Sytl2 knockout cells and ASPS null cells were also confirmed by immunohistochemical spheroid analysis (Fig. 6f). These results suggest that ASPSCR1::TFE3 induces endothelial sprouting via the Rab27a and Sytl2 axis in ASPS cells in collaboration with pericytes.

**Fig. 6: Induction of vascular network by co-culture of tumor spheroids, pericytes, and HUVECs in the microfluidic device.**

Discussion

A prominent vascular network is a hallmark of ASPS, both in morphology and biological behavior. Abundant capillary blood vessels in ASPS are associated with its slow growth and resistance to conventional chemotherapy. The vascular structure of ASPS is reproducible in both genetically engineered mouse and xenograft models transplanted with human ASPS cells^17,18,22. Our study demonstrated that angiogenic promotion occurs at the early stage of tumor growth in vivo (Fig. 1f, Supplementary Fig. 1e), indicating that this mechanism is essential for the ASPS development.

Previous studies identified numerous ASPSCR1::TFE3 targets that are involved in growth signaling, lysosomal functions, autophagy, and angiogenesis in both ASPS and fusion-positive renal cell carcinoma, with the latter exhibiting a vascular structure similar to that of ASPS^{21,22,24,25,36}. Many of these genes are believed to be involved in the important biological processes of ASPS and tumorigenesis. However, the reported targets are rather diverse, probably due to differences in model systems and the lack of appropriate biological evaluation. Furthermore, in vitro studies using cell lines are considerably limited, and the clarification of angiogenic mechanisms requires both in vivo studies and advanced co-culture techniques, such as the organ-on-a-chip system used in this study. Significant tumor-growth inhibition in vivo by ASPSCR1::TFE3 loss indicates the importance of co-proliferation between tumor cells and blood vessels in ASPS. The present study demonstrates the essential role of the ASPSCR1::TFE3 driven pathways in tumor development and angiogenesis. The similar tumor suppression and angiogenesis phenotypes and gene expression profiles between ASPSCR1::TFE3 loss and the JQ1 treatment suggests the critical role of SEs modulated by ASPSCR1::TFE3, although the mechanism by which Brd4-inhibition targets certain SEs awaits clarification. A previous study indicated that key SEs define cell lineage, stemness, plasticity, and differentiation, which are remodeled by pioneer transcription factors such as SOX9, in hair follicle stem cells³⁷. ASPSCR1::TFE3, as a pioneer factor, may also play a key role in SE modulation during ASPS development and angiogenesis.

RAB27 and SYTL/SLP proteins collaborate to facilitate cytoplasmic trafficking of vesicles, secretory granules, and target proteins, such as membrane-bound receptors^38,39. These molecules are important in non-neoplastic pathological conditions, such as degranulation of neutrophils, cytotoxic T-cells, and platelets^38,39. A RAB27A genetic mutation has been reported in the congenital disorder Griscelli syndrome type 2, in which the patients exhibit albinism and severe immune deficiencies^34,40. Although RAB27A and SYTL2 expression is upregulated in multiple cancer types⁴¹, the biological significance of this upregulation is not well understood. We previously identified Sytl1, a close homolog of Sytl2, as a direct target gene of Meis1 in AML⁴². Sytl1, a Rab27b partner in hematopoietic cells, facilitates CXCR4 membrane trafficking and promotes occupancy of the bone marrow niche by AML, indicating the importance of the Rab27/Sytl axis in the interaction between tumor cells and the microenvironment. In this study, we identified Rab27a and Sytl2 as angiogenesis promoting factors that are downstream targets of ASPSCR1::TFE3-regulated SEs. Rab27a and Sytl2 do not directly affect vascular network construction; instead, they increase the secretion of angiogenic factors that are abundant in ASPS cells. Rab27a and Sytl2 upregulation indicates the importance of targeting this pathway for effective ASPS therapy using specific inhibitors, such as Nexinhib 20. Thus, improved inhibitors of this pathway are promising therapeutic tools.

Multiple factors that promote angiogenesis were found to be upregulated in ASPS^17,18,21,43. Our present study revealed important angiogenic factors, such as PDGFB, GPNMB, and ANGPTL2, which are upregulated in ASPS, and they are included in the cargo transported from the cytoplasm to the membrane by RAB27A and SYTL2. However, we did not identify all the components sufficient for angiogenesis in ASPS. Further studies are required to clarify the complete angiogenic process of ASPS. Nevertheless, this study revealed that PDGFB is important for pericyte migration and proliferation^10,11,44, a key vascular-network component in ASPS. Accumulation of PDGFRB-positive cells were observed in an early phase of ASPS transplantation, suggesting that pericytes may be promptly migrated. Although PDGFRB is also expressed in other mesenchymal cells such as fibroblasts, the mature ASPS lesion exhibits the presence of abundant pericyte components, strongly suggesting that certain fractions of PDGFRB-positive cells might contribute to ASPS vascular network. Moreover, GPNMB is essential for tumor-cell intravasation and extravasation in ASPS, given that Gpnmb knockdown significantly reduces the interaction between ASPS and endothelial cells¹⁷. Furthermore, GPNMB induces endothelial-cell migration⁴⁵, indicating its importance in tumor vascular network formation. ANGPTL2 binds to endothelial cells and promotes vascular sprouting in collaboration with ANGPTL1^46,47.

VWF is a plasma glycoprotein that is predominantly produced by endothelial cells and megakaryocytes⁴⁸. VWF is transported to Weibel–Palade bodies, and its secretion is promoted by Rab27a during the hemostatic process^49,50. VWF also plays an important role in angiogenesis and it functions as a reservoir of angiogenic growth factors⁵¹. Although the role of VWF secreted from ASPS cells remains unclear, angiogenic factors, such as PDGFB and VEGF, possibly bind to VWF to facilitate interactions between pericytes and endothelial cells. Indeed, a previous study demonstrated that VWF deficiency in mice causes a delay in angiogenesis⁵¹.

Finally, we evaluated the importance of the ASPSCR1::TFE3 and Rab27a/Sytl2 axis using an angiogenesis model. As ASPS is characterized by an integrated vascular network comprising tumor cells, pericytes, and endothelial cells as described above, it is difficult to evaluate the modulation of angiogenic potential using a standard cell culture. The organ-on-a-chip system, using microfluidic devices and tumor spheroids, greatly improves monolayer-culture deficit⁵². In this study, we created a core shell structure containing ASPS tumor cells covered with pericytes, reflecting the alveolar structure of ASPS in vivo¹⁹. Proper and efficient interaction between ASPS and pericytes induces endothelial-cell sprouting. Significant ASPSCR1::TFE3, Rab27a, and Sytl2 contributions were highlighted in the induction of vascular sprouting. Inhibitory drugs for angiogenesis in ASPS would be evaluated using this system, enabling the development of improved and effective ASPS therapies. Rab27a-mediated transportation of cytoplasmic vesicles is involved in multiple cellular functions and strict inhibition of the function may induce unexpected effects, nevertheless, development of novel inhibitors will benefit the patients of refractory diseases such as ASPS.

Methods

All research complies with relevant ethical regulations, including approval by Japanese Foundation for Cancer Research Institutional Review Board (IRB) under license 2013-1155 and the animal care committee at the Japanese Foundation for Cancer Research under licenses 10-05-9 and 0604-3-13.

Cell lines and culture

The mouse ASPS cell lines ASPS17 and ASPS25 were established from the tumors induced in embryonic mesenchymal cells expressing ASPSCR1::TFE3 as previously described¹⁷. The human ASPS cell lines, ASPS-KY and ASPS1, are described previously^53,54. Mouse pericytes were purified from the dpc 17 mouse embryo mesenchyme by sorting the Pdgfrb+, Cd105+, and Cd31- fraction, and the cells were immortalized by introduction of the SV40 large T antigen. Aska and Yamato were obtained from Norifumi Naka⁵⁵. KH was established in our lab⁵⁶. A673, U2OS and HEK293T were purchased from ATCC (CRL-1598, HTB-96, and CRL-3216). ASPS-KY, ASPS1, Aska, Yamato, and KH were authenticated by the STR assay. None of cell lines used were under the list of known misidentified cell lines provided from the International Cell Line Authentication Committee (ICLAC). Mouse and human ASPS cell lines were grown in IMDM and RPMI1640 supplemented with 10% FBS, respectively. Mouse pericytes, Aska, Yamato, U2OS, and HEK293T cell lines were grown in DMEM with 10% FBS. A673 and KH were grown in RPMI1640 with 10% FBS. Absence of mycoplasma contamination was confirmed at regular intervals by PCR (Takara).

Allograft transplantation studies

Tumor cell transplantation experiment was performed by injecting 1 × 10⁶ ASPS cells mixed in Matrigel (Corning) into the subcutaneous regions of 6- to 8-weeks old female Balb/c nude mice. JQ1 and THZ1 were intraperitoneally administrated daily for two weeks (50 mg of JQ1 and 10 mg of THZ1). Mice were carefully observed daily, and were euthanized 17 or 25 days after transplantation of ASPS17 or ASPS-KY cells, respectively. All animal experiments described in this study were performed in strict accordance with standard ethical guidelines under the 12 h lights on/12 h lights off cycle and at 23 °C and 50% humidity. Mice were euthanized by CO₂ inhalation before tumors reached a maximum size of 2000 mm³. The studies of ours and others demonstrated that no sex predisposition in the incidence and prognosis of alveolar soft part sarcoma, validating our initial choice to use only one sex. The experiments were approved by the animal care committee at the Japanese Foundation for Cancer Research under licenses 10-05-9 and 0604-3-13.

Immunoblotting

Cells were lysed in RIPA buffer and precleaned by centrifugation at 10,000 × g for 10 min at 4 °C. Protein concentrations were measured by the DC protein assay (Bio-Rad). Equal amout of protein lysates were boiled for 5 min in sample buffer (0.5 M dithiothreitol, 25% glycerol, 2% sodium dodecyl sulfate (SDS), 60 mM Tris-HCl pH 6.8 and bromophenol blue. The samples were separated by sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on SuperSep gels (Fuji Film) and transferred onto nitrocellulose membrane (Amersham). Immunoblots were probed with primary antibodies in 5% skim milk overnight at 4 °C and respective secondary antibodies for 1 h at room temperature. Primary antibodies used were ASPSCR1 (1:1000, Sigma-Aldrich, HPA026749), Cas9 (1:1000, Novus Biologicals, NBP2-36440), c-Myc (1:1000, Cell Signaling, 5605), CCBE1 (1:1000, Affinity Biosciences, DF10092), SYNGR1 (1:1000, Cell Signaling, 20874), PDGFB (1:1000, Abcam, ab23914), VWF (1:1000, Bioss, bs4754R), RAB27A (1:1000, Cell Signaling, 69295), SYTL2 (1:1000, Proteintech, 12359), FLAG-tag (1:1000, Sigma-Aldrich, F3165), Myc-tag (1:1000, Santa Cruz Biotechnology, sc-40), GFP (1:1000, Merck Millipore, MAB3580), mCherry (1:1000, Cell Signaling, 43590), DsRed (1:1000, Clontech, 632496), a-Tubulin (1:1000, Sigma-Aldrich, T5168), and Gapdh (1:1000, HyTest, 5G4). Rabbit IgG conjugated with HRP (1:2000, Cytiva, NA934, 1:2000) was used as a secondary antibody.

Immunofluorescence

Mouse ASPS cells were fixed with 4% paraformaldehyde and were subjected to immunofluorescence using the specific antibodies and the respective fluorochrome-labeled secondary antibodies. Immunofluorescent images were photographed with a Zeiss LSM 710 laser scanning microscope with a 60x objective (Zeiss) and LSM Software ZEN 2009 (Zeiss). Captured images were analyzed using ImageJ. The mean distance of Vwf from the nucleus was calculated in 10 different cells for each condition per experiment by tracing lines (6 in each cell) from the nuclear membrane to the most distal fluorescent foci. For evaluation of 3D-culture in the microfluidic device, fluorescence and immunofluorescence images were captured using Olympus IX71 and Olympus FV3000, and recorded every other day and quantified as described in the figure legends. Antibodies used were VWF (not diluted, DAKO, N1505), FLAG-tag (1:100, Sigma-Aldrich, F7425), and goat anti-rabbit IgG conjugated with RRX (1:100, Jackson Immunoresearch, 111-295-144).

Quantitative RT-PCR (qRT-PCR)

Total RNA extraction, reverse transcription and RNA quantification were performed by standard methods. Conventional RT-PCR and real-time quantitative RT-PCR (Q-RT-PCR) were performed with a Gene Amp 9700 thermal cycler (Applied Biosystems) and a 7500 Fast Real-Time PCR System (Applied Biosystems), respectively. The sequences of the oligonucleotide primers are shown in Supplementary Data 12.

Histopathology and immunohistochemistry

For light microscopic analysis, tumor tissues were fixed with 3% formaldehyde, paraffin embedded, and stained with hematoxylin and eosin (H&E) using standard techniques. Antibodies used were mouse CD31 (1:100, Cell Signaling, 77699), PDGFRB (1:100, R & D Systems, BAF1042), RAB27A (1:100, Cell Signaling, 69295), SYTL2 (1:100, Santa Cruz Biotechnology, sc393847), VWF (1:100, Santa Cruz Biotechnology, sc365712), human CD31 (1:100, Abcam, ab28346), FLAG-tag (1:100, Sigma-Aldrich, F3165), aSMA (1:100, DAKO, MO851), TFE3 (1:100, Santa Cruz Biotechnology, sc5958), and NG2 (1:100, Millipore, AB5320). Heat-mediated antigen retrieval was performed in Tris-EDTA buffer at pH 6.0. Immunohistochemical staining was performed using the Simple Stain MAX-PO kit (Nichirei Bioscience), the Histofine SAB-PO (R) kit (Nichirei Bioscience).

Gene expression profiling

ASPS cell pellets were processed to extract total RNeasy Mini Kit (Qiagen). RNA quality was assessed using the Bioanalyzer 2100 (Agilent). The murine Genome HT MG-430 PM Array and the human HG-U133+ PM Array (Affymetrix, Santa Clara, CA, USA) were hybridized with aRNA probes generated from the total RNA samples. After staining with streptavidin-phycoerythrin conjugates, arrays were scanned using an Affymetrix GeneAtlas Scanner.

Microarray data processing and analysis

The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 100. Microarray data were analyzed using GeneSpring GX 14.9 (Agilent). Gene pathway analysis was performed using Gene Set Enrichment Analysis (GSEA) was performed using GSEA-P 2.0 software⁵⁷, and Ingenuity Pathway Analysis (Qiagen).

RNA sequencing

Total RNA was prepared (Qiagen) and quality checked. The RNA-seq libraries were made using SMARTer Stranded Total RNA-seq Kit (Takara Bio). Next generation sequencing was performed on an Illumina NextSeq 500.

RNA-seq analysis

To generate expression count matrix, row reads were trimmed to remove adaptor sequences by Skewer (v0.2.2). UMIs were extracted by umi_tools ‘extract’ and UMI adaptor sequences were also removed by cutadapt (v1.15). The processed reads were mapped to hg38 genome by STAR (v.2.7.8a), and then de-duplicated by umi_tools ‘dedup’. The mapped reads were counted by featureCounts (v.2.0.10). edgeR’s glmQLFTest (v3.32.1) was used to identify differential gene expression. We used as input groups of control and intervention experiments with a simple design with a 0 intercept ‘~0 + Group’. First, library sizes were normalized by calculating scaling factors with ‘calcNormFactors (y, method = TMM)’. Dispersions were then estimated with ‘estimateDisp (y, design = design, robust = TRUE)’, and fitted the generalized linear model using ‘glmQLFit (y, design = design)’. Finally, log2 fold-changes and false-discovery rates were calculated by glmQLFTest.

Chromatin immunoprecipitation (ChIP)-sequencing

ChIP-Seq was performed using the method previous described with modifications⁵⁸. A total of 5 × 10⁶ ASPS cells per immunoprecipitation were cross-linked with 1% formaldehyde for 10 min at room temperature. Chromatin was sheared in SDS lysis buffer containing 1% SDS, 10 mM EDTA, and 50 mM Tris pH 8.0 to an average size of 400 to 500 bp using a Covaris S220 sonicator for 15 min. ChIP was performed with 5 μg anti-histone H3K27ac (Active Motif, 39133), anti-H3K4me3 (Abcam, ab8580), anti-H3K27me3 (Millipore, 07-449), anti-FLAG (Sigma-Aldrich, F7425), anti-ASPSCR1 (Sigma-Aldrich, A026749), anti-BRD4 (Bethyl Laboratories, A301-985A100) antibodies. The antibody-bound protein/DNA complexes were immunoprecipitated using protein G magnetic beads. Immunoprecipitated DNA was then purified and subjected to secondary sonication to an average size 150 to 350 bp. Libraries were prepared according to instructions accompanying the ThruPLEX DNA-Seq kit (Rubicon Genomics). The ChIP DNA was end modified and adapters were ligated. DNA was PCR amplified with Illumina primers and Illumina-compatible indexes were added. The library fragments of approximately 300–500 bp were band-isolated from an agarose gel. The purified DNA was sequenced on an Illumina MiSeq next-generation sequencer following the manufacturer protocols.

ChIP-seq data analysis

Base calls were performed using Bowtie 2 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml). ChIP-Seq reads were aligned to the mm9 (https://www.ncbi.nlm.nih.gov/assembly/GCF_000001635.18) or hg19 (https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.13/) genome assembly using samtools 1.2 (http://www.htslib.org). Peak calling was performed using MACS1.4 (http://liulab.dfci.harvard.edu/MACS). Peak distribution was calculated by Cistrome (http://cistrome.org/ap/root). Neighbor genes on enriched genomic regions were determined using by Nucleus (https://rias.rhelixa.com). The genomic distributions of DNA-binding peaks were visualized by NGSplot (https://anaconda.org/bioconda/r-ngsplot). DNA-binding of each ChIP-seq data was visualized using IGV_2.3.80 (http://software.broadinstitute.org/software/igv). The de novo motif enrichment was performed using HOMER v 4.11.1 (http://homer.ucsd.edu/homer/motif). Super-enhancers were identified using the method previously described with the ROSE program (http://younglab.wi.mit.edu/super_enhancer_code.html)^27,59. Gene ontology analysis for nearby genes on super-enhancers were performed by GREAT version 4.0.4 (http://great.stanford.edu/public/html/).

Epigenomic CRISPR/dCas9 screening

CRISPR/Cas9-based epigenomic screening was performed according to the method described with modifications^60,61. Total of 494 SEs and active enhancers in which H3K27ac signals were reduced more than 40% by ASPSCR1::TFE3 loss were selected, and average 12.8 gRNAs per each enhancer were designed to target these enhancers using CRISPR direct (https://crispr.dbcls.jp) and GuideScan (http://www.guidescan.com) (Supplementary Data 8). 397 gRNAs for enhancers without ASPSCR1::TFE3 binding and 1000 non-target gRNAs (https://www.addgene.org/pooled-library/zhang-mouse-gecko-v2/) were designed as negative controls. Gibson overhangs were fused to sense and antisense nucleotides corresponding to each gRNA. The gRNA library was synthesized by CustomeArray and inserted into pLV-U6-gRNA-UbC-DsRed-P2A-Bsr (Addgene) using Gibson Assembly (New England BioLabs). A high titer gRNA library was constructed in Endura ElectroCompetent cells (Lucigen), and 293FT cells were transfected with the purified library DNA, psPAX2 and pCMV-VSV-G. ASPS17/dCas9-KRAB cells were generated by infecting Lenti-Ef1a-dCas9-KRAB-Puro lentivirus (Addgene) and the cells were transduced with lentivirus bearing the gRNA library at 100x fold coverage. DsRed-positive cells were sorted by FacsAria II and selected using 2 µg/mL of Blasticidin four days after infection. Then, 1 × 10⁶ infected cells were transplanted subcutaneously to nude mice 10 days after infection. Subcutaneous tumors were removed a month after transplantation and genomic DNA was extracted, PCR amplified, and subjected to target sequencing using screening primers listed in Supplementary Data 13.

Data analysis of CRISPR/dCas9 screening

gRNAs were mapped to the annotation file (0 mismatch), and read count tables were made. Sequencing reads were compared between pre-transplanted and post-transplanted ASPS 17 cells using DESeq2. MAGeCK³¹ was used to normalize the count tabled based on median normalization and fold changes, and the significance of differences was calculated. Downstream statistical analyses and generating plots were performed using MAGeCKFlute⁶².

Hi-C

The Hi-C libraries were constructed using an Arima-HiC Kit (Arima Genomics) according to the manufacturer’s instructions for Mammalian Cell Lines (A160134 v00) and Library Preparation (A160137 v00). In brief, one million cells were collected and crosslinked with 37% formaldehyde solution. DNA isolated from the crosslinked cells was digested with two restriction enzymes (^GATC and G^ANTC). After the incorporation of biotinylated nucleotides at the digested DNA ends, both ends were ligated with the spatially proximal ends. The ligated DNA was sheared into 200–600 bp fragments using the Focused-ultrasonicator M220 (Covaris) and the ligation junctions were enriched with streptavidin magnetic beads. The sequencing libraries from enriched DNA fragments were prepared with a TruSeq DNA PCR-Free Library Prep Kit (Illumina). The resulting libraries were amplified with 10 PCR cycles and purified with SPRI beads. The quality and concentration of the paired-end libraries were evaluated using the Qubit 4 Fluorometer (Thermo Fisher Scientific), the 2100 Bioanalyzer system (Agilent Technologies), and the 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific). The final libraries were sequenced on the Illumina NovaSeq 6000 sequencer with a read length of 150 bp. Reads were processed with Juicer pipeline, using reference of hg38 for human samples and mm10 for mouse samples, yielding.hic files⁶³. These files were further used for Juicebox visualization and downstream analysis, including finding loops and contact domains using Juicer tools. Loops were called by HICCUPS and those located in Chr1-22 (human), 1–19 (mouse), and X.

CRISPR/Cas9-mediated gene editing

Lentivirus plasmids containing short guided RNA (sgRNA) for Ccbe1, Pdgfb, Rab27a, Syngr1, Sytl2, and Vwf were introduced into the lentiCRISPRv2-puro vector (Addgene). The sgRNA sequences are listed in Supplementary Data 13. Knockdown efficiencies were confirmed by western blotting and/or RT-PCR.

Enzyme-linked immunosorbent assay (ELISA)

For the ELISA, 5 × 10⁴ mouse ASPS cells were seeded and cultured overnight. The culture media were collected and immediately analyzed using the mouse Gpnmb (Abcam), Vwf (Abcam), and Pdgfb (Proteintech) ELISA kits according to manufacturers’ instructions.

Fluorescence recovery after photobleaching

Trafficking of Pdgfb, Gpnmb, and Angptl2 was evaluated by FRAP following previously described procedures⁶⁴. ASPS17 and null cells were transfected with with plasmids containing, DsRed-tagged Pdgfb, Gpnmb, or Angptl2. RFP-tagged actin (Invitrogen) was used as a negative control of trafficking. FRAP images were acquired with an LSM880 confocal microscope equipped with a live cell chamber (set at 37 °C) and ZEN software (Zeiss) with a 40X objective. Cells were excited with a 561 nm laser and the emission between 566 and 689 nm recorded. Images were acquired with 12 bits image depth and 512 × 512 resolution using a pixel dwell of ~1.52 μs. At least three (n ≥ 3) pre-bleaching images were collected and then the region of interest was bleached with 100% of laser power. The recovery of fluorescence was traced at every 5 min for 1 h. For drug inhibition experiments, 10 µM of Nexinhib 20 (Tocris) was added into culture media 3 h before bleaching. Fluorescence recovery rates were corrected for internal photobleaching and background, and they were normalized to pre-photobleaching intensities as previously described⁶².

Fabrication of microfluidic device

The micropatterned master with 100 µm in height features was fabricated based on standard photolithography. SU-8 3050 (MicroChem) was coated and patterned on a 4 inch silicon wafer by exposing ultraviolet (UV) light to the top of a photomask on which the desired 3-channel patterns are printed. A mixture of PDMS (Sylgard 184, Dow-Corning) and its curing agent was mixed to a 10:1 weight ratio, poured onto the patterned master to a 5-mm thickness, degassed to remove air bubbles for 1–2 h, and cured in an oven at 80 °C for 3–4 h. The cured PDMS was removed from the wafer. The inlets (diameter: 2 mm), outlets (diameter: 6 mm), and center hole (diameter: 1 mm) for media filling and spheroid injection were punched using biopsy punches unless otherwise noted. After cleaning with adhesive tape, the PDMS device and glass coverslip were permanently bonded using oxygen plasma treatment (40 s, 50 sccm, 40 mW). Furthermore, the microfluidic devices were then stored in a 35 mm dish and cured in an oven at 80 °C for more than 2 h. After sterilization under UV for 1–2 h, the microfluidic devices were ready for cell seeding.

ASPS spheroid formation

The prewarmed DMEM was added to the dish, and the ASPS cell suspensions were transferred into 15 mL tubes and centrifuged at 1000 rpm for 3 min. The cells were resuspended at desired density. Cell suspension was then added in a prime surface 96-well plate with U-shaped bottom well (Sumitomo Bakelite), which significantly caused self-aggregation of cells, namely a spheroid. Monoculture core spheroids were prepared with a density of 5.0 × 10⁴ cells/mL in the IMDM medium for 2 days. Co-culture core-shell spheroids were initiated by core spheroid formation. After two days, the suspension culture of core spheroids was then replaced by human placental microvascular pericytes (Angio-Proteomie) suspension at a density of 7.5 × 10⁴ cells/mL in the IMDM medium for shell formation for another day. Finally, the spheroids were introduced into a microfluidic device.

In vitro angiogenesis

A spheroid was transferred into fibrin-collagen gel (2.5 mg/mL fibrinogen) (Sigma-Aldrich), 0.15 U/mL aprotinin (Sigma-Aldrich), 0.2 mg/mL collagen type I (Corning), and thrombin 0.5 U/mL (Sigma-Aldrich) in D-PBS. The spheroid suspended in gel solution was then injected through the center hole into channel 2 without leakage into channels 1 and 3 and incubate at a 37 °C CO₂ incubator for 15 min for gelation. Channels 1 and 3 were filled with EGM-2 and incubated overnight at the incubator to eliminate the bubbles at the boundary of gel and medium. For HUVEC adhesion at the gel interface, the HUVECs (5.0 × 10⁶ cells/mL in the EGM-2) were injected into channel 1. With a 90° tilt device at a 37 °C CO₂ incubator for 15 min, HUVECs adhered to the gel surface in the microfluidic device. This process was repeated for channel 3. After spheroid injection and HUVEC adhesion, the inlets and outlets of channels 1 and 3 were filled with EGM-2 and kept at 37 °C and 5% CO₂ in an incubator. For culturing cells on the device, EGM-2 was replaced daily unless otherwise noted.

Human sarcoma specimens

Alveolar soft part sarcoma, synovial sarcoma, Ewing sarcoma, myxoid liposarcoma, dermatofibrosarcoma protuberans and solitary fibrous tumor surgical specimens were obtained from The Cancer Institute Hospital. All samples were collected from 37 patients (20 females and 17 males, 5 to 87 years of age). Informed written consent was obtained from all the patients, and the study was approved by Institutional Review Board at the Japanese Foundation for Cancer Research under license 2013-1155. Patients were consecutively included in this study, therefore there were no selection of patients based on sex in this study. Twenty females and 17 males were included in this study. Gender of participants was not intentionally selected, since did not find association of the sex and gene expression profiles in sarcoma patient samples.

Data comparisons in human sarcoma samples

Six microarray studies containing 166 tumor samples that were analyzed using U133 Plus 2.0A Array (Affimetrix) were queried for gene expression. CEL files from GSE12102, GSE13433, GSE20196, GSE32569, GSE66533, and E-MTAB-1361 were downloaded. The probe sets for RAB27A, SYTL2, PDGFB, and VWF were examined.

Statistics and data reproducibility

Statistical analyses were performed using Microsoft Excel for Mac Version 16. A two-tailed Student t-test was used when comparing two groups and one-way ANOVA statistical method was used for multiple comparison. The mean ± SD of individual experiments is shown. All immunofluorescence, immuhohistochemistry, qRT-PCR and western blotting results were repeated at least twice using independently prepared samples, and similar results were obtained.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The raw RNA-seq and ChIP-seq data generated in this study have been deposited in the NCBI Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo) under the accession number GSE215265 and GSE189163, respectively. The raw Hi-C data generated in this study have been deposited in the DDBJ Sequenced Read Archive under the accession numbers DRR330423 and DRR330424. The reused publicly available data for gene expression are available in the NCBI Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo) under the accession number GSE12102⁶⁵, GSE13433²¹, GSE20196⁶⁶, GSE32569¹⁴, GSE66533⁶⁷, and in the EMBL-EBI ArrayExpress (https://www.ebi.ac.uk/biostudies/arrayexpress) under the accession number E-MTAB-1361⁶⁸. The following human genome accessions were used: The NCBI accession of the UCSC hg19 genome is GCA_000001405.1. The following mouse genome accessions were used: GRCM37/mm9 assembly via UCSC under GCA_000001635.1. The remaining data are available within the Article, Supplementary Information or Source Data file. Source data are provided with this paper.

Materials availability

Plasmids generated in this study are available upon request (T.N.)

References

Ye, W. The complexity of translating anti-angiogenesis therapy from basic science to the clinic. Dev. Cell 37, 114–125 (2016).
Article CAS PubMed Google Scholar
Lewis, C. E., Harney, A. S. & Pollard, J. W. The multifaceted role of perivascular macrophages in tumors. Cancer Cell 30, 18–25 (2016).
Article CAS PubMed PubMed Central Google Scholar
Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985–1000 (2002).
Article PubMed PubMed Central Google Scholar
Song, S., Ewald, A. J., Stallcup, W., Werb, Z. & Bergers, G. PDGFRB+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 7, 870–879 (2005).
Article CAS PubMed PubMed Central Google Scholar
Mogler, C. et al. Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin. EMBO Mol. Med. 9, 741–749 (2017).
Article CAS PubMed PubMed Central Google Scholar
Qian, C. N., Huang, D., Wondergem, B. & Teh, B. T. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer 115, 2282–2289 (2009).
Article CAS PubMed Google Scholar
Sugino, T. et al. Morphological evidence for an invasion-independent metastasis pathway exists in multiple human cancers. BMC Med. 2, 9 (2004).
Article PubMed PubMed Central Google Scholar
Fang, J. H. et al. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology 62, 452–465 (2015).
Article CAS PubMed Google Scholar
Gerhardt, H. & Betsholtz, C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 314, 15–23 (2003).
Article PubMed Google Scholar
Furuhashi, M. et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res. 64, 2725–2733 (2004).
Article CAS PubMed Google Scholar
Hellstrom, M., Kalen, M., Lindahl, P., Abramsson, A. & Betsholtz, C. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126, 3047–3055 (1999).
Article CAS PubMed Google Scholar
Folpe, A. L. & Deyrup, A. T. Alveolar soft-part sarcoma: a review and update. J. Clin. Pathol. 59, 1127–1132 (2006).
Article CAS PubMed PubMed Central Google Scholar
Jambhekar, N. A. & Ladanyi, M. Alveolar soft part sarcoma. In: The Who Classification of Tumours Editorial Board (eds). Soft Tissue and Bone Tumours. 297–299 (WHO, 2020).
Kummar, S. et al. Cediranib for metastatic alveolar soft part sarcoma. J. Clin. Oncol. 31, 2296–2302 (2013).
Article CAS PubMed PubMed Central Google Scholar
Stacchiotti, S. et al. Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist 23, 62–70 (2018).
Article CAS PubMed Google Scholar
Wilky, B. A. et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 20, 837–848 (2019).
Article CAS PubMed Google Scholar
Tanaka, M. et al. Modeling alveolar soft part sarcoma unveils novel mechanisms of metastasis. Cancer Res. 77, 897–907 (2017).
Article CAS PubMed Google Scholar
Vistica, D. T. et al. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to anti-angiogenic therapy. J. Pediatr. Hematol. Oncol. 31, 561–570 (2009).
Article CAS PubMed PubMed Central Google Scholar
Ladanyi, M. et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 18q25. Oncogene 20, 48–57 (2001).
Article CAS PubMed Google Scholar
Selvarajah, S. et al. High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin. Cancer Res. 20, 1521–1530 (2014).
Article CAS PubMed PubMed Central Google Scholar
Stockwin, L. H. et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer 9, 22 (2009).
Article PubMed PubMed Central Google Scholar
Goodwin, M. L. et al. Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment. Cancer Cell 26, 851–862 (2014).
Article CAS PubMed PubMed Central Google Scholar
Fang, R. et al. Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma. Oncogene 40, 3303–3317 (2021).
Article CAS PubMed Google Scholar
Kobos, R. et al. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated. Aberrant transcription factor, the ASPSCR1::TFE3 fusion oncoprotein. J. Pathol. 229, 743–754 (2013).
Article CAS PubMed PubMed Central Google Scholar
Baba, M. et al. TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease. Mol. Cancer Res. 17, 1613–1626 (2019).
Article CAS PubMed PubMed Central Google Scholar
Boulay, G. et al. Cancer-specific retargeting of BAF complexes by a prion-like domain. Cell 171, 163–178 (2017).
Article CAS PubMed PubMed Central Google Scholar
Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319 (2013).
Article CAS PubMed PubMed Central Google Scholar
Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777–790 (2013).
Article CAS PubMed PubMed Central Google Scholar
Delmore, J. E. et al. BET domain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917 (2011).
Article CAS PubMed PubMed Central Google Scholar
Kwiakowski, M. et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616–620 (2014).
Article ADS Google Scholar
Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 15, 554 (2014).
Article PubMed PubMed Central Google Scholar
Fukuda, M. Rab27 effectors, pleiotropic regulators in secretory pathways. Traffic 14, 949–963 (2013).
Article CAS PubMed Google Scholar
Simon, M. P. et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15, 95–98 (1997).
Article CAS PubMed Google Scholar
Menasche, G. et al. Biochemical and functional characterization of Rab27a mutations occurring in Griscelli syndrome patients. Blood 101, 2736–2742 (2003).
Article CAS PubMed Google Scholar
Johnson, J. L. et al. Identification of neutrophil exocytosis inhibitors (Nexinhibs), small molecule inhibitors of neutrophil exocytosis and inflammation. J. Biol. Chem. 291, 25965–25982 (2016).
Article CAS PubMed PubMed Central Google Scholar
Covell, D. G., Wallqvist, A., Kenney, S. & Vistica, D. T. Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets. PLoS ONE 7, e48023 (2012).
Article ADS CAS PubMed PubMed Central Google Scholar
Adam, R. C. et al. Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. Nature 521, 366–370 (2015).
Article ADS CAS PubMed PubMed Central Google Scholar
Yasuda, T. & Fukuda, M. Slp2-a controls renal epithelial cell size through regulation of Rap-ezrin signaling independently of Rab27. J. Cell Sci. 127, 557–570 (2013).
PubMed Google Scholar
Menasche, G. et al. A newly identified isoform of Slp2a associates with Rab27a in cytotoxic T cells and participates to cytotoxic granule secretion. Blood 112, 5052–5062 (2008).
Article CAS PubMed Google Scholar
Ohbayashi, N. et al. Functional characterization of two RAB27A missense mutations found in Griscelli syndrome type 2. Pigment Cell Melanoma Res. 23, 365–374 (2010).
Article CAS PubMed Google Scholar
Hendrix, A. et al. Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. Int. J. Cancer 133, 843–854 (2013).
Article CAS PubMed Google Scholar
Yokoyama, T. et al. MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis. J. Clin. Invest. 126, 1664–1678 (2016).
Article PubMed PubMed Central Google Scholar
Lazar, A. J. F. et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin. Cancer Res. 13, 7314–7321 (2007).
Article CAS PubMed Google Scholar
Zhang, Y. et al. Platelet-specific PDGFB ablation impairs tumor vessel integrity and promotes metastasis. Cancer Res. 80, 3345–3358 (2021).
Article Google Scholar
Maric, G., Rose, A. A. N., Annis, M. G. & Siegel, P. M. Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. OncoTargets Ther. 6, 839–852 (2013).
CAS Google Scholar
Farhat, N., Mamarbachi, A. M., Thorin, E. & Allen, B. G. Cloning, expression and purification of functionally active human angiopoietin-like protein 2. SpringerPlus 3, 337 (2014).
Article PubMed PubMed Central Google Scholar
Kubota, Y. et al. Cooperative interaction of Angiopoietin-like proteins 1 and 2 in zebrafish vascular development. Proc. Natl Acad. Sci. USA 102, 13502–13507 (2005).
Article ADS CAS PubMed PubMed Central Google Scholar
Lenting, P. J., Christophe, O. D. & Denis, C. V. Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 125, 2019–2028 (2015).
Article CAS PubMed Google Scholar
Nightingale, T. D. et al. Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells. Blood 113, 5010–5018 (2009).
Article CAS PubMed PubMed Central Google Scholar
Bierings, R. et al. The interplay between the Rab27A effectors Slp4-a and MyRIP controls hormone-evoked Weibel-Palade body exocytosis. Blood 120, 2757–2767 (2012).
Article CAS PubMed PubMed Central Google Scholar
Ishihara, J. et al. The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing. Blood 133, 2559–2569 (2019).
Article CAS PubMed PubMed Central Google Scholar
Nashimoto, Y. et al. Vascularized cancer on a chip: The effect of perfusion on growth and drug delivery of tumor spheroid. Biomaterials 229, 119547 (2019).
Article PubMed Google Scholar
Kamijyo, A. & Shinoda, K. Establishment of human alveolar soft sarcoma cell line ASPS-KY. J. Jpn. Orthop. Assoc. 79 S598 (2005).
Kenney, S. et al. ASPS-1 a novel cell line manifesting key features of alveolar soft part sarcoma. J. Pediatr. Hematol. Oncol. 33, 360–368 (2011).
Article CAS PubMed PubMed Central Google Scholar
Naka, N. et al. Synovial sarcoma is a stem cell malignancy. Stem Cells 28, 1119–1131 (2010).
Article CAS PubMed Google Scholar
Tanaka, M. et al. Ewing’s sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. J. Clin. Invest. 124, 3061–3074 (2014).
Article CAS PubMed PubMed Central Google Scholar
Subramanian, A., Kuehn, H., Gould, J., Tamayo, P. & Mesirov, J. P. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics 23, 3251–3253 (2007).
Article PubMed Google Scholar
Shimizu, R. et al. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. Cancer Sci. 109, 2907–2918 (2018).
Article CAS PubMed PubMed Central Google Scholar
Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).
Article CAS PubMed PubMed Central Google Scholar
Klann, T. S. et al. CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat. Biotechnol. 35, 561–568 (2017).
Article CAS PubMed PubMed Central Google Scholar
Klann, T. S., Crawford, G. E., Reddy, T. E. & Gersbach, C. A. Screening regulatory element function with CRISPR/Cas9-based epigenome editing. Methods Mol. Biol. 1767, 447–480 (2018).
Article CAS PubMed Google Scholar
Wang, B. et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat. Protoc. 14, 756–780 (2019).
Article CAS PubMed PubMed Central Google Scholar
Durand, N. C. et al. Juicebox provides a visualization system for Hi-C contact maps with unlimited zoom. Cell Syst. 3, 99–101 (2016).
Article CAS PubMed PubMed Central Google Scholar
Rademacher, D. J., Cabe, M. & Bakowska, J. C. Fluorescence recovery after photobleaching of yellow fluorescent protein tagged p62 in aggresome-like induced structures. J. Vis. Exp. 145, e59288 (2019).
Google Scholar
Scotlandi, K. et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J. Clin. Oncol. 27, 2209–2216 (2009).
Article CAS PubMed Google Scholar
Nakayama, R. et al. Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am. J. Surg. Pathol. 34, 1599–1607 (2010).
Article PubMed Google Scholar
Sun, W. et al. Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma. Mod. Pathol. 28, 1214–1224 (2015).
Article CAS PubMed PubMed Central Google Scholar
Bertucci, F. et al. Gene expression profiling of solitary fibrous tumors. PLoS ONE 8, e64497 (2013).
Article ADS CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

The authors thank Rikuka Shimizu, Yasuyo Teramura, Tomoko Takahara, Liyin Yang, and Hinako Ishizaki for technical assistance, Ryohei Nakamura for data evaluation, and Robert Shoemaker for providing ASPS1 cells. This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (16K07131 and 19K07702 to M.T., and 26250029 to T.N.), and by a Grant-in-Aid Project for Cancer Research and Therapeutic Evolution from the Japan Agency for Medical Research and Development (17cmA106609 to T.N., 20cm0106277 to T.N. and R.Y., 21ak0101170 to T.N., and 22ama221206 to M.T. and R.Y.). This work was also supported by JSPS KAKENHI Grant Number 16H06279 (PAGS).

Author information

Authors and Affiliations

Division of Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
Miwa Tanaka, Mizuki Homme, Yukari Yamazaki & Takuro Nakamura
Department of Experimental Pathology, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan
Miwa Tanaka, Yukari Yamazaki & Takuro Nakamura
Project for Cancer Epigenomics, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
Miwa Tanaka, Kohei Kumegawa & Reo Maruyama
Department of Micro Engineering, Graduate School of Engineering, Kyoto University, Kyoto, Japan
Surachada Chuaychob, Ruyin Lyu & Ryuji Yokokawa
Division of Cell Biology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
Mizuki Homme
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
Kyoko Yamashita
Department of Orthopedic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Keisuke Ae & Seiichi Matsumoto
Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
Wei Qu
Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan
Yohei Miyagi

Authors

Miwa Tanaka
View author publications
You can also search for this author in PubMed Google Scholar
Surachada Chuaychob
View author publications
You can also search for this author in PubMed Google Scholar
Mizuki Homme
View author publications
You can also search for this author in PubMed Google Scholar
Yukari Yamazaki
View author publications
You can also search for this author in PubMed Google Scholar
Ruyin Lyu
View author publications
You can also search for this author in PubMed Google Scholar
Kyoko Yamashita
View author publications
You can also search for this author in PubMed Google Scholar
Keisuke Ae
View author publications
You can also search for this author in PubMed Google Scholar
Seiichi Matsumoto
View author publications
You can also search for this author in PubMed Google Scholar
Kohei Kumegawa
View author publications
You can also search for this author in PubMed Google Scholar
Reo Maruyama
View author publications
You can also search for this author in PubMed Google Scholar
Wei Qu
View author publications
You can also search for this author in PubMed Google Scholar
Yohei Miyagi
View author publications
You can also search for this author in PubMed Google Scholar
Ryuji Yokokawa
View author publications
You can also search for this author in PubMed Google Scholar
Takuro Nakamura
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

M.T.: investigation, formal analysis, data curation, visualization, validation, funding acquisition and writing-original draft. S.C.: data curation, investigation, methodology and visualization. M.H.: investigation and validation. Y.Y.: investigation. R.L.: investigation. K.Y.: resources. K.A.: resources. S.M.: resources. K.K.: data curation and formal analysis. R.M.: data curation and formal analysis. W.Q.: formal analysis and data curation. Y.M.: resources. R.Y.: methodology, conceptualization, funding acquisition and supervision. T.N.: conceptualization, investigation, project administration, supervision, funding acquisition, writing—original draft and editing.

Corresponding authors

Correspondence to Miwa Tanaka or Takuro Nakamura.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature Communications thanks Chunliang Li, Nicolo Riggi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Supplementary Data 3

Supplementary Data 4

Supplementary Data 5

Supplementary Data 6

Supplementary Data 7

Supplementary Data 8

Supplementary Data 9

Supplementary Data 10

Supplementary Data 11

Supplementary Data 12

Supplementary Data 13

Reporting Summary

Source data

Source Data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Cite this article

Tanaka, M., Chuaychob, S., Homme, M. et al. ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma. Nat Commun 14, 1957 (2023). https://doi.org/10.1038/s41467-023-37049-z

Download citation

Received: 03 January 2022
Accepted: 01 March 2023
Published: 07 April 2023
DOI: https://doi.org/10.1038/s41467-023-37049-z

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.